cjc1295 and ipamorelin benefits CJC-1295 and Risks Peptide Therapy: CJC-1295 + Ipamorelin:

(1992, Biochem J) demonstrated that IGF-1 and its variants including Long R3 IGF-1 are anabolic in dexamethasone-treated rats, confirming the utility of IGF-1 LR3 in models of catabolic states and muscle wasting where native IGF-1 activity is suppressed by glucocorticoid-driven IGFBP upregulation

This compound is intended strictly for scientific investigation and analytical use

Log your symptoms and side effects so your provider can respond quickly

Body composition changes typically become visible between weeks 4 and 8, depending on diet and training

Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics